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http://dx.doi.org/10.1016/j.jaip.2014.07.016OBJECTIVE: To compare exacerbation rates and health care
utilization for patients with asthma who initiate BFC versus FSC
therapy.
METHODS: This retrospective cohort comparative effectiveness
study queried medical and pharmacy data for patients with
asthma from a large managed care data repository that covers
major US population centers. The patients were 12 to 64 years
old, with ‡12 months of pre- and postindex enrollment and ‡1
pharmacy claim(s) for BFC or FSC initiated during June 1,
2007, and September 30, 2010; the ﬁrst prescription ﬁll date was
deﬁned as the index date. Patients with other respiratory diseases
and/or cancer were excluded. Exacerbation was deﬁned as
asthma-related hospitalization, emergency department visit, and/
or oral corticosteroid prescription ﬁll. Cohorts were matched by
using propensity scores.
RESULTS: A total of 3043 patients per cohort were matched and
balanced. During the 12 months following the initiation the BFC
cohort had lower adjusted exacerbations per person year versus the
FSC cohort (0.85 vs 0.93;RR0.92, 95%CI [0.85-0.99]), lower oral
corticosteroid ﬁll rates, and fewer asthma-related emergency
department visits but comparable asthma-related hospitalization.
CONCLUSIONS: Asthma exacerbation was lower for BFC
versus FSC initiators due to lower rates of oral corticosteroid use
and asthma-related emergency department visits, which indicate
better treatment effectiveness of those patients initiated with
BFC compared with FSC.  2014 The Authors. Published by
Elsevier Inc. on behalf of the American Academy of Allergy,
Asthma & Immunology. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/) (J Allergy Clin Immunol Pract 2014;2:719-26)719
Abbreviations used
BFC- Budesonideeformoterol fumarate dihydrate combination
DCI- Deyo-Charlson index
ED- Emergency department
FSC- Fluticasone propionateesalmeterol combination
GERD- Gastroesophageal reﬂux disease
ICS- Inhaled corticosteroid
LABA- Long-acting b2-adrenergic agonist
LTRA- Leukotriene receptor antagonist
OCS- Oral corticosteroid
OR- Odds ratio
PDC- Proportion of days covered
RR- Rate ratio
SABA- Short-acting b2-adrenergic-agonist
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Asthma, a common respiratory condition that results from
inﬂammation in both large and small airways,1,2 directly impacts
an estimated 24.6 million people in the United States.3 Total
health care costs directly attributable to asthma care in the United
States were estimated at $37.2 billion (in 2007).4 Medical
Expenditure Panel Survey data for 2002 to 2007 showed that
asthma imposed an incremental society-wide cost of $56 billion
(adjusted to 2009 US$).5 Treatment goals include achieving
adequate control and reducing the risk of exacerbations and
serious impairment.6 Long-term controller medications, such as
inhaled corticosteroids (ICS), are recommended by the current
Expert Panel Report-3 for patients with persistent asthma.7 For
patients ages 12 years, the guidelines for the diagnosis and
management of asthma indicate that the addition of a long-acting
b2-adrenergic agonist (LABA) be given equal weight to the option
of increasing the ICS alone for patients inadequately controlled
on ICS alone and for those patients with high levels of impair-
ment and elevated risks of asthma exacerbation.7 Currently, 3
ICS-LABA combination therapies are approved for use in the
United States: budesonideeformoterol fumarate dihydrate
(BFC),8 ﬂuticasone propionateesalmeterol combinations (FSC)
therapy,9 and mometasoneeformoterol fumarate dihydrate.10
Clinical trials that assess BFC and FSC showed mixed results
in the United States.11 Lasserson et al11 reviewed 5 randomized
studies (5537 adults) in the Cochrane Airways Group register
that compared ﬁxed-dose FSC and BFC of adults and children
diagnosed with asthma. Treatment durations were a minimum of
12 weeks; most of the studies assessed treatment for a 6-month
period. Study populations had prior treatment with inhaled
steroids (ﬂuticasone/salmeterol or orbudesonide/formoterol) and
had moderate or mild airway obstruction. Because of the
imprecision of the estimated effects of asthma exacerbations,
deﬁnitive conclusions about the superiority of either agent
remain indeterminate.11 With the growing recognition of the
impact of asthma management on health care resources and
costs, payers espouse the urgent need for real-world effectiveness
data on asthma therapies beyond clinical efﬁcacy and lung
function.12,13 In particular, data on the effect of controller
therapies on avoidable asthma exacerbation and health care
resource utilization are important.Two population-based retrospective studies, in Canada14 and
in Germany,13 evaluated comparative effectiveness of BFC versus
FSC in asthma management. By using a matched cohort design,
the Canadian study showed that, compared with patients on
FSC, patients who received BFC were signiﬁcantly less likely to
require asthma-related emergency department (ED) visits or
hospitalizations and oral corticosteroid (OCS) ﬁlls, and required
less short-acting b2-adrenergic-agonists (SABA) per week.
14 The
German study demonstrated that patients with chronic asthma
who initiated BFC therapy had a greater probability of treatment
success with fewer severe asthma exacerbations and fewer OCS
prescription ﬁlls.13 However, the device (dry powder inhaler) and
a commonly used indication (use for maintenance and reliever
therapy) for BFC approved in these countries are not approved in
the United States. To our knowledge, no studies to date have
compared the 2 agents by using the US device (a pressurized
metered dose inhaler) and with the US approved indication. The
objective of the current study was to evaluate the real-world
effectiveness of the ICS-LABA combination by comparing
asthma exacerbation rates and health care resource utilization
over a 1-year period after initiation of BFC and FSC with devices
and indications approved in the United States.
METHODS
Data source and study design
This retrospective cohort study (NCT01623544) used inte-
grated medical and pharmacy claims data to describe and compare
differences in key outcomes among patients with asthma who
initiated BFC versus FSC treatments between June 1, 2007, and
September 30, 2010. The index date was deﬁned as the date of the
ﬁrst pharmacy claim for either study medication. The patients
were assigned to BFC or FSC cohorts based on their ﬁrst pre-
scription ﬁll. Study data were acquired from the HealthCore In-
tegrated Research Database (HealthCore Inc., Wilmington, Del),
a diverse longitudinal administrative claims repository that con-
tains data from commercial health plans in the northeast, midwest,
south, and west regions of the United States. Researchers only had
access to de-identiﬁed patient data, and patient anonymity and
conﬁdentiality were safeguarded in compliance with the Health
Insurance Portability and Accountability Act. Institutional review
board approval was not required for this observational study.
Study population
Patients were considered to have a claims-based asthma
diagnosis if they had 1 inpatient visit with a primary diagnosis
code for asthma or 1 ED visit with an asthma diagnosis or with 2
or more medical claims (any visit combination) with an asthma
diagnosis in the 12 months before the index date. Generic
Product Identiﬁer Codes (see Table E1 in this article’s Online
Repository at www.jaci-inpractice.org) were used to identify
patients who received BFC or FSC combination therapy. In-
ternational Classiﬁcation of Diseases, Ninth Revision Clinical
Modiﬁcation codes (493.0x, 493.1x, or 493.9x) were used to
identify asthma.
Inclusion criteria. Patients were required to be between 12
and 64 years of age on the index date and to have 1 BFC or
FSC prescription ﬁll during the intake period. A second ﬁll for
the same ICS-LABA combination in the 12 months after the
index prescription (postindex period) was required for inclusion
in the study. For inclusion, patients had to be naive (no
TABLE I. Asthma exacerbation rate during the 12-month postindex period
Unadjusted rate* Adjusted rate†
RR† 95% CI† P value†BFC (n [ 3043) FSC (n [ 3043) BFC (n [ 3043) FSC (n [ 3043)
Asthma exacerbation rate 0.83 0.89 0.85 0.93 0.92 0.85-0.99 .0255
Sensitivity analysis
Asthma exacerbation
rate excluding the ﬁrst
30 d after the indexz
0.75 0.79 0.70 0.75 0.93 0.86-1.02 .1189
Number of patients N ¼ 2785 N ¼ 2785 N ¼ 2785 N ¼ 2785
Asthma exacerbation rate,
excluding patients with
an index date between
Jun 1, 2007, and Nov
30, 2007x
0.82 0.89 0.87 0.95 0.92 0.84-0.99 .0340
*The unadjusted exacerbation rate is the total number of exacerbations in the study population divided by total person years. Because all persons will contribute exactly 1 y, this
rate is simply (no. exacerbations)/(no. patients).
†Adjusted exacerbation rates and the RR are from a negative binomial regression model. Statistical comparisons compared BFC with FSC (reference group), in which RR is rate
(BFC)/rate (FSC). Model covariates include age at index (continuous), sex, health plan type, geographic region, index year, index physician specialty, DCI score, asthma-related
inpatient hospitalization (yes-no during the preindex period), asthma-related ED visits (yes-no during the preindex period), OCS use (yes-no during the preindex period), and
preindex comorbid conditions (allergic rhinitis, gastroesophageal reﬂux disease, major depressive disorder, obesity, sinusitis, sleep apnea [yes-no for each]).
zFollow-up for asthma exacerbations started 30 d after the index date to ensure that the patients were allowed adequate exposure to the study medication before attributable
outcomes were assessed. All the persons contributed 335 d (1 year minus 30 d, excluded from the start of the postindex period).
xThe start of the intake period corresponds with the launch of BFC in the US market. All the patients on BFC with an index date during the ﬁrst 6 mo of the intake period (Jun 1,
2007 to Nov 30, 2007) and their matches were excluded because of the possibility that patients on BFC during this time were characteristically different than the BFC population
as a whole.
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the preindex period.
Exclusion criteria. Patients diagnosed with chronic obstruc-
tive pulmonary disease, other respiratory diseases or inﬂammatory
diseases, and any type of cancer (for International Classiﬁcation of
Diseases, Ninth Revision Clinical Modiﬁcation codes, see
Table E2 in this article’s Online Repository at www.jaci-
inpractice.org) were excluded. Patients with chronic steroid use
(patients with 1 or more prescription ﬁlls that totaled a 60-day
supply of continuous OCS treatment) and patients with a claim
for Xolair (omalizumab) during the preindex period also were
excluded. Patients with prescription claims for more than 1 type
of ICS-LABA combination on the index date or with prescription
claims for an ICS-LABA combination therapy that was different
from the index therapy during the 12-month postindex period (ie,
“switchers”) also were excluded.
Outcome measurements
Asthma exacerbation rates. The primary outcome was
the rate of asthma exacerbation. An asthma exacerbation was
deﬁned as an inpatient hospitalization with a primary diagnosis
of asthma, an ED visit with a diagnosis of asthma, or a pharmacy
claim for OCS medications. The rate of asthma exacerbation was
deﬁned as the total number of asthma exacerbations during the
postindex period for all patients in the cohort divided by the total
follow-up time in person years.
Health care resource utilization. All-cause and asthma-
related health care resource utilization during the 12-month
postindex period was compared for patients who initiated BFC
and FSC. Inpatient visits, ED visits, outpatient and/or ofﬁce
visits, and all procedures and prescriptions were included in the
calculations.
Proportion of days covered. The proportion of days
covered with the index medication was calculated for eachindividual as the total days’ supply prescribed during the post-
index period, including the index ﬁll, divided by the total follow-
up time (365 days).
Statistical analysis
Statistical analysis was performed for each postindex outcome
between the propensity-score matched BFC and FSC cohorts.
Propensity matching details are provided in Supplement E1 (in
this article’s Online Repository at www.jaci-inpractice.org). A
negative binomial model with a logarithmic link function was
used to assess asthma exacerbation rates during the 12-month
postindex period. Asthma-related health care utilization was
analyzed by using generalized linear models from the negative
binomial distribution, with a logarithmic link function.
Dichotomous outcomes were analyzed by using logistic regres-
sion to obtain odds ratios (OR), and Poisson regression was used
to obtain risk ratios. All adjusted models controlled for patient
demographics, asthma-related resource use, and comorbid con-
ditions. A full list of covariates is provided in the footnotes to
Tables I to III. All statistical analyses were performed by using
SAS version 9.2 (SAS Institute Inc, Cary, NC), with a statistical
signiﬁcance level of .05.
Sensitivity analyses
Because prescribing information indicates that it could take 1
to 2 weeks before the maximum beneﬁts of BFC and FSC are
observed with patients,8,10 a sensitivity analysis was conducted by
using a second follow-up period, which started 31 days after the
index date and continued until the end of the remaining 365
days, as shown in the Supplement E2 (in this article’s Online
Repository at www.jaci-inpractice.org).
RESULTS
Patient disposition
A total of 508,000 patients had at least 1 prescription for ICS-
LABA combination treatment during the intake period.
TABLE II. Components of asthma exacerbation during the 12-month postindex period
BFC
(n [ 3043) FSC (n [ 3043)
Adjusted means*
Effect
estimate† 95% CI† P valueBFC FSC
Asthma exacerbations 1
No. (%) 1292 (42.5) 1341 (44.1)
Risk ratio 0.96 0.90-1.02 .2196
OR 0.93 0.84-01.04 .1917
Asthma exacerbations 2
No. (%) 607 (19.9) 639 (21.0)
Risk ratio 0.95 0.87-1.03 .1959
OR 0.93 0.81-1.05 .2434
Asthma exacerbations, no. exacerbations (mean  SD) 0.83  1.4 0.89  1.48 0.85 0.93 0.08 0.14 to 0.01 .0255
OCS ﬁlls 1
No. (%) 1216 (40.0) 1274 (41.9)
Risk ratio 0.95 0.89-1.02 .1329
OR 0.92 0.82-1.02 .1048
OCS ﬁlls 2
No. (%) 560 (18.4) 589 (19.4)
Risk ratio 0.94 0.86-1.03 .1986
OR 0.93 0.81-1.06 .2635
OCS ﬁlls (no.), mean  SD 0.77  1.36 0.82  1.43 0.73 0.79 0.07 0.12 to 0.01 .0299
Asthma-related hospitalization 1z
No. (%) 45 (1.5) 46 (1.5)
Risk ratio 0.97 0.85-1.11 .6362
Odds ratio 1.01 0.66-1.56 .9651
Asthma-related hospitalization  2z
No. (%) 5 (0.2) 8 (0.3)
Asthma hospitalizations (no.), mean  SD 0.02  0.15 0.02  0.16 0.01 0.01 0.00 0.00-0.00 .6390
LOS, mean  SDx 5.91  6.5 6.28  5.6 5.4 5.4 0.04 1.40 to 2.00 .9638
Asthma-related ED visits 1
No. (%) 228 (7.5) 258 (8.5)
Risk ratio 0.90 0.81-1.00 .0540
OR 0.88 0.73-1.07 .1910
Asthma-related ED visits 2
No. (%) 39 (1.3) 64 (2.1)
Risk ratio 0.63 0.55-0.72 <.0001
OR 0.61 0.40-0.92 .0180
Asthma-related ED visits (no.), mean  SD 0.09  0.37 0.12  0.49 0.08 0.10 0.02 0.03 to 0.00 .0486
Other asthma-related utilization
Asthma-related outpatient visits 1
No. (%) 2462 (80.9) 2469 (81.1)
Risk ratio 1.00 0.97-1.03 .9067
OR 0.99 0.87-1.12 .8400
Asthma-related outpatient visits 2
No. (%) 1844 (60.6) 1855 (61.0)
Risk ratio 0.99 0.95-1.04 .7854
OR 0.98 0.88-1.09 .7001
Asthma-related outpatient no. visits, mean  SD 3.49  5.7 3.52  5.8 2.8 2.8 0.00 0.15 to 0.16 .9666
ICS monotherapy ﬁlls 1
No. (%) 277 (9.1) 311 (10.2)
Risk ratio 0.87 0.79-0.97 .0145
OR 0.86 0.72-1.02 .0874
ICS monotherapy ﬁlls 2
No. (%) 148 (4.9) 174 (5.7)
Risk ratio 0.83 0.74-0.94 .0031
OR 0.82 0.66-1.03 .0932
(continued)
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TABLE II. (Continued)
BFC
(n [ 3043) FSC (n [ 3043)
Adjusted means*
Effect
estimate† 95% CI† P valueBFC FSC
ICS monotherapy ﬁlls (no.) mean  SD 0.23  1.06 0.26  1.07 0.28 0.36 -0.08 0.13 to 0.01 .0325
SABA ﬁlls 1
No. (%) 202 (66.4) 2166 (71.2)
Risk ratio 0.94 0.90-0.98 .0027
OR 0.80 0.72-0.90 <.0001
SABA ﬁlls 2
No. (%) 1328 (43.6) 1404 (46.1)
Risk ratio 0.95 0.89-1.01 .1019
OR 0.91 0.82-1.00 .0568
SABA ﬁlls (no.), mean  SD 2.09  2.78 2.26  2.89 2.4 2.6 0.18 0.32 to 0.03 .0221
PDC for index medication, mean  SD 0.40  0.23 0.43  0.25 0.46 0.49 0.03 0.04 to 0.02 <.0001
LOS, Length of stay; PDC, proportion of days covered.
*Adjusted means are calculated from regression models by adjusting for all model covariates: age at index (continuous), sex, health plan type, geographic region, index year,
index physician specialty, DCI score, asthma-related inpatient hospitalization (yes-no during the preindex period), asthma-related ED visits (yes-no during the preindex period),
OCS use (yes-no during the preindex period), and preindex comorbid conditions (allergic rhinitis, gastroesophageal reﬂux disease, major depressive disorder, obesity, sinusitis,
sleep apnea [yes-no for each]).
†The type of effect estimate depends on the outcome and statistical model: ORs for categorical variables are from logistic regression models; risk ratios for categorical variables
are from Poisson regression models; the differences in adjusted means for continuous variables are from negative binomial regression models; comparisons are of compared
BFC with FSC (reference group); ie, adjusted mean difference ¼ AdjMean (BFC) eAdjMean (FSC) and OR ¼ Odds (BFC)/Odds (FSC). All statistical tests control for model
covariates mentioned above.
zAsthma-related events include inpatient hospitalizations with a primary diagnosis for asthma and asthma-related ED visits are those patients who have a diagnosis for asthma in
any position.
xLOS is calculated with patients who had at least 1 hospitalization.
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the BFC and FSC groups, respectively. Excluding patients who
switched study medication during follow-up resulted in the loss
of 2.7% of patients, with similar rates within each group: 2.8%
of patients on FSC and 2.5% of patients on BFC. After pro-
pensity score matching, there were 3043 patients in each cohort
(Figure 1).
Characteristics of matched cohorts at baseline
The cohorts were well balanced, and the standardized difference
between groups was less than 10% for any given baseline variable
after matching (Supplement E1; Table III in this article’s Online
Repository at www.jaci-inpractice.org). Patients in the BFC and
FSC cohorts had a mean SD age of 40 14.8 years, and 63.5%
were women. The distribution of comorbid conditions within
each cohort is shown in Table III. ThemeanDeyo-Charlson index
(DCI) score was similar for each cohort (0.3). Similar proportions
of patients on BFC and those on FSC were seen within each
specialty, with allergists/immunologists and pulmonologists
making up a combined 40.9% and 40.2%, respectively. Patients
treated with BFC and those treated with FSC had similar asthma
controller medication use during the 12-month preindex period:
ICS (38.1% vs 37.0% with at least 1 ﬁll), LABA (7.4% vs 6.2%),
leukotriene receptor antagonist (LTRA) (35.0% vs 34.4%), and
theophylline use (1.2% vs 1.4%), respectively.
Asthma exacerbation rates
As shown in Table I, the BFC cohort had a lower unadjusted
asthma exacerbation rate compared with the FSC cohort, 0.83
versus 0.89, respectively. Adjusted exacerbation rates during the
treatment period were lower for the BFC cohort compared with
the FSC cohort (adjusted rate ratio [RR] 0.92 [95% CI, 0.85-
0.99]). On evaluation of the components of asthma exacerbationrates, compared with FSC, the BFC cohort had fewer OCS ﬁlls
(mean number of ﬁlls for BFC, 0.73; FSC. 0.79; difference0.07
[95% CI, 0.12 to 0.01]), and fewer ED visits (mean number
of visits for BFC, 0.08; FSC, 0.10; difference 0.02 [95%
CI, 0.03 to 0.00]), and comparable asthma-related hospitali-
zation rates (mean number of visits for BFC, 0.01; FSC, 0.01;
difference 0.0 [95% CI, 0.00-0.00]), as reported in Table II.
A descriptive, unadjusted analysis of exacerbation rates by index
medication dose was performed. The majority, 72%, of patients
on BFC initiated on the high dose of 160 mg ICS, and 73.5% of
patients on FSC who took the powder formulation initiated on 1
of the higher doses: 250 mg (60.2%) or 500 mg ICS (13.3%). The
patients on high-dose BFC had an exacerbation rate of 0.88 events
per person year and those who initiated high-dose powder FSC
had an exacerbation rate of 0.95 (0.86 for the patients on 250 mg
and 1.33 for the patients on 500 mg). Patients on lower-dose BFC
(80 mg) and those on FSC (100 mg) had similar exacerbation rates
(0.68 vs 0.66, respectively). Furthermore, more patients on FSC
were receiving ICS therapy (excluding the ICS-LABA combina-
tion) during the postindex period (FSC 10.2% vs BFC 9.1%; OR
0.86 [95% CI, 0.72-1.02]), and a greater proportion of patients
ﬁlled an SABA prescription (FSC 71.2% vs BFC 66.4%; OR 0.80
[95% CI, 0.72-0.90]) after initiation of ICS-LABA. Additional
analyses that modeled the relative risks resulted in risk ratios that
were in the same direction as the ORs and statistically signiﬁcant
for both ICS and SABA use, although closer to 1.0, and can be
found in Table II.
Sensitivity analyses demonstrated that this difference was
similar but no longer signiﬁcant when exacerbations within the
ﬁrst 30 days were excluded (adjusted RR 0.93 [95% CI, 0.86-
1.02]). Results were similar to the primary analysis when
excluding patients on BFC who initiated therapy during the ﬁrst
6 months of the intake period (which corresponds to the initial
TABLE III. Characteristics of propensity score matched cohorts
Matched cohort characteristics BFC (n [ 3043) FSC (n [ 3043) 95% CI P value*
Age (y), mean  SD 40.1  14.8 39.7  14.8 0.43 to 1.06 .4023
Men, no. (%) 1108 (36.40) 1115 (36.60) 0.89-1.10 .8522
Health plan type, no. (%)
HMO 443 (14.60) 439 (14.40) 0.88-1.17 .8842
PPO 2353 (77.30) 2,335 (76.70) 0.92-1.17 .5833
POS 141 (4.60) 158 (5.20) 0.70-1.12 .3134
Geographic region, no. (%)
Northeast 603 (19.80) 629 (20.70) 0.84-1.08 .4069
Midwest 900 (29.60) 893 (29.40) 0.91-1.13 .8440
South 876 (28.80) 888 (29.20) 0.88-1.10 .7346
West 664 (21.80) 633 (20.80) 0.94-1.20 .3319
DCI comorbidity score, mean  SD 0.35  0.7 0.33  0.7 0.02 to 0.06 .2994
Comorbidities, no. (%)
Allergic rhinitis 1451 (47.70) 1441 (47.40) 0.92-1.12 .7974
Sinusitis 957 (31.50) 940 (30.90) 0.92-1.14 .6380
GERD 406 (13.30) 409 (13.40) 0.86-1.15 .9101
Anxiety 228 (7.50) 255 (8.40) 0.74-1.07 .2004
Major depressive disorder 111 (3.70) 110 (3.60) 0.77-1.32 .9454
Obesity 167 (5.50) 170 (5.60) 0.79-1.22 .8665
Sleep apnea 206 (6.80) 206 (6.80) 0.82-1.22 1
Prescriber specialty, no. (%)
Allergist/Immunologist 823 (27.10) 802 (26.40) 0.93-1.16 .5429
Pulmonologist 421 (13.80) 419 (13.80) 0.87-1.16 .9408
Pediatrics 135 (4.40) 131 (4.30) 0.81-1.32 .8020
Internal medicine 519 (17.10) 527 (17.30) 0.86-1.12 .7858
Family/general practitioner 731 (24.00) 761 (25.00) 0.84-1.07 .3714
GERD, Gastroesophageal reﬂux disease; HMO, health maintenance organization; POS, point of service; PPO, preferred provider organization.
*For the overall distribution, and most useful for testing the variable of interest.
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0.84-0.99]). Differences in exacerbation rates were notable in the
number of OCS ﬁlls in the postindex period as well as the
number of asthma-related ED visits. The frequency of asthma-
related inpatient visits was comparable for the 2 cohorts.DISCUSSION
This ﬁrst US comparative effectiveness study of BFC versus
FSC combination therapies for asthma in a real-world population
found lower rates of asthma exacerbation in the BFC cohort
compared with the FSC cohort (adjusted RR 0.92 [95% CI,
0.85- 0.99]). Sensitivity analyses demonstrated similar differ-
ences. These ﬁndings are consistent with prior studies conducted
outside of the US. A Canadian retrospective matched cohort
study evaluated the real-world effectiveness of BFC (n ¼ 1449)
versus FSC (n ¼ 9381) in patients with asthma, as measured by
the need for acute care and ambulatory medical visits.14 On
adjusting for all known confounding variables, the investigators
found that patients treated with BFC were signiﬁcantly less likely
to have an ED visit for asthma (RR 0.72 [95% CI, 0.54-0.96]),
asthma-related hospitalization (RR 0.50 [95% CI, 0.25-0.99]),
or ﬁll an OCS prescription (RR 0.83 [95% CI, 0.72-0.95]), and
used less SABA per week (mean difference, 1.1 dose/wk [95%
CI, 1.7 to 0.5 dose/wk]) than those treated with FSC.
Although our study found no difference in asthma-related
inpatient hospitalizations, our observations were consistent with
the directionality of the ﬁndings by Blais et al.14A German study15 that used administrative claims data from
2001 to 2005 compared outcomes for the postindex year for pa-
tients who received BFC (n¼ 1456) and those who received FSC
(n ¼ 982). Patients in the 2 cohorts had similar baseline charac-
teristics, and asthma exacerbation was deﬁned as 1 OCS pre-
scription ﬁll, asthma-related inpatient hospitalization, and/or
referral. The patients with chronic asthma who initiated BFC
therapy had fewer severe exacerbations (33.4% reduction; P ¼
.0123), fewer OCS prescriptions (31.5% reduction; P ¼ .0082),
and less SABA use (13.3% reduction; P ¼ .2297) compared with
FSC, after controlling for baseline characteristics. The ﬁndings
from our study were similar to the trend of reductions in OCS and
SABA use, with fewer exacerbations reported in the German
study.15 In essence, the exacerbation rates reported in our study
were similar to those in both the German15 and Canadian14
studies, although these comparisons are limited because there were
slight differences in how these studies deﬁned exacerbation rates.
The magnitude of the estimate of sensitivity analysis excluding
exacerbations within the ﬁrst 30 days of treatment (RR, 0.93) is
almost exactly that of the primary outcome (RR, 0.92); however,
the exclusion of some exacerbations resulted in a loss of statistical
power, which may account for the loss of statistical signiﬁcance
of an already marginally signiﬁcant result. The objective of this
sensitivity analysis was to examine the stability and validity of the
ﬁnding; given the similar effect estimates, we believe that the
primary result is not being overly inﬂuenced by exacerbations
that occur in the brief period of time before the beneﬁt of either
study medication takes effect.
2010)
FIGURE 1. Disposition of study population.
J ALLERGY CLIN IMMUNOL PRACT
VOLUME 2, NUMBER 6
TUNCELI ETAL 725The current study results indicated that patients who initiated
BFC therapy had a lower asthma exacerbation rate compared
with those who initiated FSC. These results are based on
matched 1-to-1 patient cohorts that were well balanced on many
potential confounding variables and are consistent with ﬁndings
from previous retrospective observational studies.14,15 The cur-
rent study adds the US perspective to the paucity of data of real-
world comparative effectiveness for 2 of the most commonly
used ICS-LABA medications for the treatment of moderate-to-
severe persistent asthma. This type of data facilitates a better
understanding of clinical trial results based primarily on re-
sponses. The impact of therapy on tangible outcomes important
to both patients and health care providers, including the utili-
zation and cost of treatment, can be assessed by using observa-
tional data and is increasingly gaining importance for all
stakeholders.12,13
The current study results should be interpreted within the
context of study limitations. To our knowledge, as of now, no
studies have compared BFC and FSC among patients by using
the US pressurized metered dose inhaler device and the US
approved indication. This could limit the extrapolation of the
study’s ﬁndings outside the United States. This study was based
on administrative claims data that have inherent limitations,
including the absence of clinical indicators of asthma disease
severity. Asthma-related utilization was based on having a claim
for asthma, which either could overestimate or underestimate the
actual utilization for any given patient or population. Our
analysis also may be subject to exposure misclassiﬁcation due toimprecision in the attribution of exacerbations or secondary
outcomes to the index medication or other treatments and/or
drugs during the follow-up period. The generalization of these
results may only be applicable to similar commercially insured
patient populations and have limited utility in a population 65
years old and older.
This study demonstrated that patients with asthma who
initiated BFC had a lower rate of asthma exacerbations, fewer ﬁlls
of additional asthma controller medication, and fewer SABA
prescription claims. These results must be interpreted within the
context of claims database limitations, and future studies in
different patient populations may provide additional evidence
regarding the real-world effectiveness of these agents. Also, this
database analysis can be used to provide evidence for future
clinical research. The results of this effectiveness study should be
conﬁrmed by a well-designed prospective real-world pragmatic
clinical trial.
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Propensity Score Matching
The BFC and FSC cohorts were not randomly assigned to the
treatment groups, which may lead to comparisons between co-
horts being confounded by selection bias. To ensure compara-
bility and to reduce selection bias, the propensity score matching
technique was used to adjust for measured confounders and to
create more comparable BFC and FSC cohorts.E1-E3 The pro-
pensity score for each individual was estimated as the probability
of receiving BFC therapy (vs FSC), conditional on observed
baseline characteristics. Logistic regression was used to calculate
the scores. By using estimated propensity scores, a patient in the
BFC cohort was matched with a patient in the FSC cohort who
had a similar predictive probability when using Greedy nearest
neighbor 1:1 matching with no replacement. The cohorts were
considered well balanced for a given variable if the standardized
difference between cohorts was 10% or less.E1-E3
The success of the propensity score model is judged by
whether the balance was improved between 2 cohorts with
respect to the selected variables. We started with the most
comprehensive logistic model and gradually eliminated variables
to achieve a ﬁnal propensity score model. Propensity scores
calculated from the ﬁnal model were used to match 2 cohorts for
analysis that provided the best balance of the selected variables
between the 2 cohorts, while retaining maximum sample size.
The following variables were used in the logistic model to pro-
duce propensity scores:
 Dependent variable. Flag for patient indexing BFC (in
modeling, the probability that this variable equals 1).
 Independent variables. Sex (ﬂag for female), age (categorically:
12-17, 18-44, 45-64 years old) region (categorically: northeast,
midwest, south, west), index year (ﬂags for 2007, 2008, and
2009), prescribing physician type (ﬂags for allergist/immunol-
ogist, pulmonologist, pediatrician, internal medicine, family
medicine/general practice, and other), previous asthma-related
inpatient hospitalization (ﬂag for >0 events), previous asthma-
related outpatient visits (ﬂags for 0 visits and 1 visit; and the
continuous count), previous OCS use (continuous count of
ﬁlls), previous ICS use (ﬂag for 0 ﬁlls, 1 ﬁll, 2þ ﬁlls), previous
LTRA use (categorically: 0 ﬁlls, 1 ﬁll, 2þ ﬁlls), previous LABA
use (ﬂags for 0 ﬁll, 1 ﬁll, 2þ ﬁlls), previous SABA use (cate-
gorically: 0 ﬁlls, 1 ﬁll, 2þ ﬁlls), allergic rhinitis (ﬂag for previous
diagnosis), gastroesophageal reﬂux disease (ﬂag for previous
diagnosis), major depressive disorder (ﬂag for previous
diagnosis).
 Interaction terms. Prescribing physician type (categorically) *
index year (categorically), region (categorically) * index year
(categorically), prescribing physician type (categorically) * re-
gion (categorically).
Before the matching algorithm was performed, the 2 cohorts
were separated into their own data sets and were sorted by
propensity scores (low to high). Sorting was done so that
matching can be replicated in the future as long as the data are
sorted the same way before initiating the algorithm. The patient
with the lowest propensity score in the BFC cohort was selected
to ﬁnd a matching patient in the FSC cohort. By using esti-
mated propensity scores, a patient in the BFC cohort was
matched with a patient in the FSC therapy cohort who had asimilar predicted probability when using the Greedy nearest
neighbor 1:1 matching technique (with no replacement).E1
First, the algorithm was run to ﬁnd matches with differences in
propensity scores of <107 and then it was run for the
remaining subjects to ﬁnd matches with differences <106.
This pattern continued up to 101, after which no further
matches were made. After the ﬁrst patient in the BFC cohort
was either matched or not matched with a patient from the FSC
cohort, the patient in the BFC cohort with the next lowest
propensity score was selected to ﬁnd a match and so on.
Random numbers were assigned to all the patients on FSC (by
using random number generation with a speciﬁed seed of
1234567), so that, if 2 or more patients on FSC have the same
propensity score and are considered the best match for patient
on BFC, the patient with the numerically lowest random
number was chosen as the match. The distributions of the
propensity scores before and after matching are shown in
Figure E1 (in this article’s Online Repository at www.jaci-
inpractice.org). The distributions were similar before match-
ing, and there were no outliers in either group, which gave all
the patients a chance to be matched, while minimizing selection
bias.
The balance on key prespeciﬁed variables that were unbal-
anced before propensity score matching are shown in Table E1.
Treatment cohorts were considered well balanced for a given
variable if the standardized difference between the cohorts was
10% or less. The use of standardized differences for assessing
balance in propensity score matching was described in Austin2
and deﬁned as:
d ¼ ð100  jxBFC  xFSC jÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2BFCþs2FSC
2
q for continuous variables;
and by
d ¼

100  pBFC  pFSC

ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pBFCð1pBFCÞþpFSCð1pFSCÞ
2
q for dichotomous variables:
All the variables were well below the standardized difference
threshold of d ¼ 10.0, with all but one having values <5.0. Only
79 patients on BFC were not matched. Because FSC had a much
larger population to begin with, only those most similar to their
FSC counterparts were kept. The patients on FSC who were not
matched tended to be those who indexed during 2007 as
opposed to later years, were prescribed their medication by a
family medicine/general practice or internal medicine physician
as opposed to an allergist/immunologist or pulmonologist, and
were less likely to have prior asthma medications but were more
likely to have a prior ED or inpatient visit.SUPPLEMENT E2. SENSITIVITY ANALYSIS
Thirty-Day Period
Prescribing information indicates that it could take 1 to 2
weeks before the maximum beneﬁts of BFC and FSC are
observed in patients,E4,E5 and a prior study allowed a 30-day
window between treatment initiation and outcomes measur-
ements.E6 To ensure that patients had adequate exposure to the
medications before treatment outcomes were measured, a sensi-
tivity analysis was conducted by using a second follow-up period,
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726.e2 TUNCELI ETALwhich started 31 days after the index date and continued until
the end of remaining 365 days. In addition, because the start of
the intake period corresponded with the launch of BFC in the
United States, it was possible that the patients who received BFC
had different characteristics from the entire BFC population. A
second sensitivity analysis excluded patients on BFC and their
FSC matches, with index dates between June 1, 2007, and
November 30, 2007 (see Figure E2 in this article’s Online Re-
pository at www.jaci-inpractice.org).
SENSITIVITY MEASURES
Exacerbation rate
Both adjusted and unadjusted asthma exacerbations rates, the
primary outcome measure, are shown in Table E2.
Switchers
Before excluding the patients who had a ﬁll for a nonindex
ICS-LABA during the postindex period (2.7% of all the pa-
tients), these patients were examined alongside patients who did
not switch ICS-LABA therapy. This analysis also was done before
matching the cohorts and the descriptive analysis evaluated both
cohorts combined, and did not differentiate between BFC and
FSC. Most baseline and preindex tables that were included in the
main analysis were replicated for this analysis, along with the
primary outcome and asthma-related health care utilization
during the postindex period. The primary outcome, includingthe individual pieces that make up the primary outcome, for
switchers (n ¼ 317) and nonswitchers (n ¼ 11,299) are shown
in Table E3 (in this article’s Online Repository at www.jaci-
inpractice.org). Patients who ﬁlled a nonindex ICS-LABA had
more than twice the number of exacerbations than patients who
did not switch (RR 2.13 [95% CI, 1.82-2.49]). The primary
result was driven by OCS use (RR 2.09), whereas even bigger
differences were seen for inpatient hospitalizations (RR 3.02) and
ED visits (RR 2.23). Generic Product Identiﬁer (GPI) codes are
provided in Table E4.
FIGURE E1. Distribution of propensity scores before and after matching.
Day 1
Index date
30-day 
treatment uptake
Day 31 Day 365
Asthma exacerbations captured
FIGURE E2. The period for sensitivity analysis.
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TABLE E1. Characteristics of cohorts before and after propensity score matching
All BFC, no. (%)
(n [ 3122)*
All FSC, no. (%)
(n [ 8177)* Std diff†
Matched BFC,
no. (%) (n [ 3043)z
Matched FSC,
no. (%) (n [ 3043)z Std diff†
Age (for each category)
12-17 y 378 (12.1) 1137 (13.9) 5.34 374 (12.3) 367 (12.1) 0.70
18-44 y 1385 (44.4) 3484 (42.6) 3.54 1341 (44.1) 1372 (45.1) 2.05
45-64 y 1359 (43.5) 3556 (43.5) 0.08 1328 (43.6) 1304 (42.9) 1.59
Men and boys 1124 (36.0) 2994 (36.6) 1.27 1108 (36.4) 1115 (36.6) 0.48
Prescriber specialty
Allergist/immunologist 864 (27.7) 1412 (17.3) 25.13 823 (27.0) 802 (26.4) 1.56
Pulmonologist 442 (14.2) 758 (9.3) 15.24 421 (13.8) 419 (13.8) 0.19
Pediatrician 135 (4.3) 521 (6.4) 9.11 135 (4.4) 131 (4.3) 0.64
Internal medicine 521 (16.7) 1705 (20.9) 10.68 519 (17.1) 527 (17.3) 0.70
Family/general practitioner 736 (23.6) 2547 (31.1) 17.05 731 (24.0) 761 (25.0) 2.29
Nonphysician 135 (4.3) 386 (4.7) 1.91 132 (4.3) 138 (4.5) 0.96
Other specialtyx 69 (2.2) 306 (3.7) 9.03 69 (2.3) 65 (2.1) 0.90
Unknownjj 220 (7.0) 542 (6.6) 1.66 213 (7.0) 200 (6.6) 1.70
Comorbid conditions
Allergic rhinitis 1502 (48.1) 3136 (38.4) 19.80 1,451 (47.7) 1441 (47.4) 0.66
Sinusitis 989 (31.7) 2357 (28.8) 6.22 957 (31.4) 940 (30.9) 1.21
GERD 419 (13.4) 920 (11.3) 6.60 406 (13.3) 409 (13.4) 0.29
Major depressive disorder 114 (3.7) 401 (4.9) 6.19 111 (3.6) 110 (3.6) 0.18
Obesity{ 177 (5.7) 454 (5.6) 0.51 167 (5.5) 170 (5.6) 0.43
Sleep apnea 210 (6.7) 487 (6.0) 3.16 206 (6.8) 206 (6.8) 0.00
ICS use
0 ﬁlls 1888 (60.5) 6206 (75.9) 33.57 1,884 (61.9) 1918 (63.0) 2.31
1 ﬁll 380 (12.2) 791 (9.7) 8.02 366 (12.0) 371 (12.2) 0.50
2þ ﬁlls 854 (27.4) 1180 (14.4) 32.20 793 (26.1) 754 (24.8) 2.94
LABA use
0 ﬁlls 2846 (91.2) 7938 (97.1) 25.35 2,819 (92.6) 2,856 (93.9) 4.85
1 ﬁll 47 (1.5) 52 (0.6) 8.46 40 (1.3) 36 (1.2) 1.18
2þ ﬁlls 229 (7.3) 187 (2.3) 23.76 184 (6.0) 151 (5.0) 4.76
LTRA use
0 ﬁlls 2003 (64.2) 5765 (70.5) 13.56 1,979 (65.0) 1996 (65.6) 1.17
1 ﬁll 257 (8.2) 624 (7.6) 2.22 249 (8.2) 247 (8.1) 0.24
2þ ﬁlls 862 (27.6) 1788 (21.9) 13.34 815 (26.8) 800 (26.3) 1.12
SABA use
0 ﬁlls 805 (25.8) 2494 (30.5) 10.50 796 (26.2) 802 (26.4) 0.45
1 ﬁll 760 (24.3) 2026 (24.8) 1.01 737 (24.2) 736 (24.2) 0.08
2þ ﬁlls 1557 (49.9) 3657 (44.7) 10.33 1,510 (49.6) 1,505 (49.5) 0.33
OCS use
0 ﬁlls 1473 (47.2) 4147 (50.7) 7.07 1443 (47.4) 1456 (47.8) 0.86
1 ﬁll 846 (27.1) 2197 (26.9) 0.52 830 (27.3) 820 (26.9) 0.74
2þ ﬁlls 803 (25.7) 1833 (22.4) 7.73 770 (25.3) 767 (25.2) 0.23
Asthma-related outpatient/ofﬁce visits
0 104 (3.3) 604 (7.4) 18.08 104 (3.4) 92 (3.0) 2.23
1 97 (3.1) 463 (5.7) 12.50 97 (3.2) 101 (3.3) 0.74
2þ 2921 (93.6) 7110 (87.0) 22.43 2,842 (93.4) 2,850 (93.7) 1.07
Asthma-related ED visits
0 2662 (85.3) 6528 (79.8) 14.35 2,594 (85.2) 2567 (84.4) 2.47
1þ 460 (14.7) 1649 (20.2) 14.35 449 (14.8) 476 (15.6) 2.47
Asthma-related inpatient visits
0 3017 (96.6) 7778 (95.1) 7.63 2941 (96.6) 2946 (96.8) 0.92
1þ 105 (3.4) 399 (4.9) 7.63 102 (3.4) 97 (3.2) 0.92
GERD, Gastroesophageal reﬂux disease; LTRA, Leukotriene receptor antagonist; std diff, standardized difference.
*All eligible patients before matching via the propensity score matching algorithm.
†A value 10 is considered well balanced.; this method is not inﬂuenced by sample size, ie, the alternative of using P values, which may ﬁnd clinically irrelevant differences
statistically signiﬁcant solely due to large sample sizes; std diff ¼ (100  │p_BFCep_FSC j)/O((p_BFC  (1  p_BFC) þ p_FSC  (1  p_FSC))/2).
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TABLE E2. Asthma exacerbation rate during the 12-month postindex period
Unadjusted rate* Adjusted rate†
RR† 95% CI† P value†BFC (n [ 3043) FSC (n [ 3043) BFC (n [ 3043) FSC (n [ 3043)
Asthma exacerbation rate, excluding
the ﬁrst 30 d after the indexz
0.75 0.79 0.70 0.75 0.93 0.86-1.02 .1189
Number of patients (excluding patients
with an index date between June 1, 2007,
and November 30, 2007)
n ¼ 2785 n ¼ 2785
Asthma exacerbation rate, excluding
patients with an index date between
Jun 1, 2007, and Nov 30, 2007x
0.82 0.89 0.87 0.95 0.92 0.84-0.99 .0340
*The exacerbation rate is the total no. exacerbations in the study population divided by total person years. Here each person contributed 335 d, ie, approximately 0.9178 y.
†Adjusted exacerbation rates and the RR are from a negative binomial regression model; the statistical comparisons compare BFC with FSC (reference group), in which RR is
rate (BFC) e rate (FSC). Model covariates include age at index (continuous), sex, health plan type, geographic region, index year, index physician specialty, DCI score, asthma-
related inpatient hospitalization (yes-no during the preindex period), asthma-related ED visits (yes-no during the preindex period), OCS use (yes-no during the preindex period),
and preindex comorbid conditions (allergic rhinitis, gastroesophageal reﬂux disease, major depressive disorder, obesity, sinusitis, sleep apnea [yes-no for each]).
zFollow-up for asthma exacerbations started 30 d after the index date to ensure that the patients were allowed adequate exposure to the study medication before attributable
outcomes were assessed. All the persons contributed 335 d (1 y minus 30 d excluded from the start of the postindex period).
xThe start of the intake period corresponds with the launch of BFC in the US market. All the patients on BFC with an index date during the ﬁrst 6 mo of the intake period (Jun 1,
2007, to Nov 30, 2007), and their matches were excluded because of the possibility that the patients on BFC during this time were characteristically different than the BFC
population as a whole.
zEligible patients matched via the propensity score matching algorithm; matched patients made up the analytic data set.
xOther specialties include anesthesiology/pain management, cardiology, dermatology, emergency medicine, endocrinology/metabolism, gastroenterology, geriatrics, hema-
tology, infectious disease, nephrology, neurology, nuclear medicine, obstetrics/gynecology, oncology, ophthalmology, otolaryngology, physical medicine/rehabilitation,
podiatry, psychiatry, radiology, rheumatology, surgery, urology.
jjPhysician specialty was not speciﬁed in pharmacy claim for index medication, and there was no asthma-related medical claim within 1 mo of the index date.
{Deﬁned by using the International Classiﬁcation of Diseases, Ninth Revision Clinical Modiﬁcation diagnosis codes.
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TABLE E3. Asthma exacerbation rate during the 12-month postindex period for “switchers” vs “nonswitchers”*
Nonswitchers (n [ 11,299)† Switchers (n [ 317)†
RRz 95% CIMean – SD Median Mean – SD Median
Asthma exacerbation ratex 0.87  1.46 0 1.84  2.10 1 2.13 1.82-2.49
Asthma-related inpatient hospitalizationsjj 0.02  0.17 0 0.06  0.27 0 3.02 1.91-4.77
Asthma-related ED visits 0.11  0.43 0 0.25  0.70 0 2.23 1.59-3.12
OCS ﬁlls{ 0.73  1.33 0 1.53  1.85 1 2.09 1.77-2.46
*Switchers are deﬁned as those patients who ﬁlled a nonindex ICS-LABA combination at any point during the 12-mo postindex period and were excluded from the study;
nonswitchers are deﬁned as those who did not ﬁll a nonindex ICS-LABA combination during the 12-mo postindex period and were included in the study.
†Includes patients before propensity score matching but who met all other inclusion-exclusion criteria up to step 4 of the attrition table.
zThe rate (switchers)/rate (nonswitchers); in this case, the rate is equal to the mean, so the RR is equal to mean (switchers)/mean (nonswitchers).
xThe exacerbation rate is the total no. exacerbations in the study population divided by total person years; because all persons contributed exactly 1 y, this rate is simply
(no. exacerbations)/(no. patients).
jjThose hospitalizations with a primary diagnosis for asthma.
{Includes only OCS ﬁlls that were not within 5 days of an inpatient hospitalization or ED visit.
TABLE E4. Generic product identifier codes
Name of medication By dose Generic product identifier code
BFC (Symbicort, Astra Zeneca) Aerosol 80-4.5 mg 44209902413220
Aerosol 160-4.5 mg 44209902413240
FSC (Advair, Glaxo Smith Kline) Aerosol 45-21 mg 44209902703250
Aerosol 115-21 mg 44209902703260
Aerosol 230-21 mg 44209902703270
Powder 100-50 mg/dose 44209902708020, 44209902706320
Powder 250-50 mg/dose 44209902708030, 44209902706330
Powder 500-50 mg/dose 44209902708040, 44209902706340
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